КУРД Джон (US),ХЭНДИСАЙДЗ Дамиан (US),ХАРТ Чарльз (US),КРОЛЛ Стюарт (US)
申请号：
RU2013102398/15
公开号：
RU2013102398A
申请日:
2011.06.27
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method for treating blood cancer, comprising administering a therapeutically effective amount of a hypoxia-activated prodrugs, selected from the group consisting of TH-281, TH-302 and TH-308 to a subject in need of such treatment, whereby the treatment is carried raka.2. A method according to claim 1, wherein the blood cancer that is being treated is selected from the group consisting of multiple myeloma, acute leukemia, the late stages of chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), high-risk, myelofibrosis (MF) in an advanced stage or relapsed or refractory chronic lymphocytic leukemia (CLL) .3. A method according to claim 2, wherein the blood cancer that is being treated is an acute leukemia, which is a relapsed or refractory acute leykemii.4 form. A method according to claim 2, wherein the blood cancer being treated is an acute leukemia which is either relapsed or refractory forms of acute lymphoblastic leukemia (ALL) or relapsed or refractory forms of acute myelogenous leukemia (AML) .5. A method according to any one of claims 1-4, wherein the patient can not apply the standard himioterapiyu.6. A method according to any one of claims 1-4, wherein the hypoxia activated prodrug administered is a TH-302.7. A method according to claim 6, wherein the TH-302 is administered as a single agent therapy for five consecutive days, or within five days of eight consecutive days at a cycle length of 21 days, and a therapeutically effective amount is from 120 mg / m / day to 575 mg / m / den.8. A method according to claim 6, wherein the TH-302 is administered as a single agent therapy to treat set1. Способ лечения рака крови, включающий введение терапевтически эффективного количества активируемого гипоксией пролекарства, выбранного из группы, состоящей из TH-281, TH-302 и TH-308, пациенту, которому необходимо такое лечение, посредством чего осуществляется лечение рака.2. Способ по п.1, при этом рак крови, который подвергают лечению, выбран из групп
